IP Library Granted Patent US 10,040,751
Granted Patent B2
US 10,040,751 · App. 14/873,056 · Granted Aug 7, 2018

Intermediates for macrocyclic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,040,751
App. No.
14/873,056
Granted
Aug 7, 2018
Kind
B2
Abstract

The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Claims (33)

1. A process for preparing a compound of formula (G):

wherein R 1 is C 1 -C 4 alkyl and PG 1 is an amine protecting group; the process comprising:

(a) contacting a compound of formula (A):

with a compound of formula (B):

in the presence of an azodicarboxylate reagent and a phosphine reagent, or in the presence of a combined Mitsunobu reagent, to form a compound of formula (C):

wherein X is halogen or triflate and PG 2 is an ester protecting group;

(b) contacting the compound of formula (C) with a reducing agent to form a compound of formula (D):

(c) contacting the compound of formula (D) with a compound of formula (E):

in the presence of a palladium catalyst, optionally a copper salt and/or optionally an organic base to form a compound of formula (F):

and

(d) contacting the compound of formula (F) with hydrogen in the presence of a metal catalyst to form the compound of formula (G).

2. The process of claim 1 , wherein the compound of formula (G) is:

3. The process of claim 1 , wherein the compound of formula (B) is selected from the group consisting of:

wherein PG 2 is an ester protecting group.

4. The process of claim 1 , wherein X is iodine.

5. The process of claim 1 , wherein PG 1 is a carbamate protecting group.

6. The process of claim 1 , wherein PG 1 is selected from the group consisting of tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz) and allyloxycarbonyl (Alloc).

7. The process of claim 1 , wherein PG 2 is an alkyl group or an alkyl group substituted with an aryl group.

8. The process of claim 1 , wherein the azodicarboxylate reagent is selected from the group consisting of diethylazodicarboxylate (DEAD) and diisopropylazodicarboxylate (DIAD).

9. The process of claim 1 , wherein the phosphine reagent is selected from the group consisting of triphenylphosphine and tributylphosphine.

10. The process of claim 1 , wherein the combined Mitsunobu reagent is a triphenylphosphine-diisopropylazodicarboxylate (DIAD) adduct.

11. The process of claim 1 , wherein the reducing agent is selected from the group consisting of an aluminum hydride and a borohydride.

12. The process of claim 1 , wherein the reducing agent is selected from the group consisting of diisobutylaluminum hydride (DIBAL-H), lithium aluminum hydride (LAH), and lithium borohydride.

13. The process of claim 1 , wherein the palladium catalyst is selected from the group consisting of dichlorobis(triphenylphosphine)palladium(II), dichlorobis(acetonitrile)-palladium(II), dichlorobis(benzonitrile)palladium(II), tetrakis(triphenyl-phosphine)palladium(0) and tris(dibenzylideneacetone)dipalladium(0).

14. The process of claim 1 , wherein the copper salt is a copper halide.

15. The process of claim 1 , wherein the copper salt is not present.

16. The process of claim 1 , wherein the organic base is selected from the group consisting of a dialkylamine, a trialkylamine and an aromatic amine.

17. The process of claim 1 , wherein the organic base is not present.

18. The process of claim 1 , wherein (c) is conducted in the presence of a phosphine.

19. The process of claim 1 , wherein the metal catalyst is palladium on carbon or platinum oxide.

20. The process of claim 1 , wherein contacting the compound of formula (A) with a compound of formula (B) in the presence of an azodicarboxylate reagent and a phosphine reagent, or in the presence of a combined Mitsunobu reagent, to form a compound of formula (C) is replaced by contacting the compound of formula (A) with a compound of formula (H):

wherein Y is OH, R 1 is C 1 -C 4 alkyl and PG 7 is an ester protecting group, in the presence of a base to form the compound of formula (C).

21. The process of claim 20 , wherein the base is selected from the group consisting of a hydrogen carbonate salt, a carbonate salt, a trialkylamine and an aromatic amine.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →